Galeterone

Tier C — Watch / trade

Galeterone

Tokai

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：AR, CYP17A1

Indications (approved)：Pancreatic cancer, Prostate cancer

Regional status

Phase II

2012-12-01

Discontinued

2015-06-01

China

Japan

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 1

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 4 · Total yield 1.10 g (Galeterone)

GALE-001853-23-6GALE-0021865-56-1GALE-00351-17-2GALE-004851895-78-8GALE-005851895-79-9API · Galeterone

Code	CAS No.	Intermediate
GALE-001	853-23-6	(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
GALE-002	1865-56-1	(3S,8R,9S,10R,13S,14S)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
GALE-003	51-17-2	1H-benzo[d]imidazole
GALE-004	851895-78-8	(3S,8R,9S,10R,13S,14S)-17-(1H-benzo[d]imidazol-1-yl)-16-formyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
GALE-005	851895-79-9	(3S,8R,9S,10R,13S,14S)-17-(1H-benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

ProcessRoute 2Steps 2 · Total yield 134.00 kg (Galeterone)

GALE-006979-02-2GALE-0072174-13-2API · Galeterone

Code	CAS No.	Intermediate
GALE-006	979-02-2	(3S,8R,9S,10R,13S,14S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
GALE-007	2174-13-2	(3S,8R,9S,10R,13S,14S)-17-((Z)-1-(hydroxyimino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

Frequently asked questions

What are the approved indications of Galeterone?

Approved indications include: Pancreatic cancer, Prostate cancer.

When does the Galeterone patent expire?

No public expiry year is available for Galeterone yet; this page updates once verified.

How many synthesis routes are recorded for Galeterone?

2 synthesis routes are recorded; the shortest is 2 steps with 134.00 kg (Galeterone) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Galeterone intermediates?

All intermediates in Galeterone routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Galeterone intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-13